Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (AU2012272950) Self-buffering protein formulations

Office : Australia
Application Number: 2012272950 Application Date: 21.12.2012
Publication Number: 2012272950 Publication Date: 17.01.2013
Publication Kind : B2
IPC:
A61K 39/395
C12P 21/08
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
P
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21
Preparation of peptides or proteins
08
Monoclonal antibodies
Applicants: Amgen Inc.
Inventors:
Agents: FPA Patent Attorneys Pty Ltd
Priority Data: 60/690,582 14.06.2005 US
Title: (EN) Self-buffering protein formulations
Abstract: front page image
(EN) The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use. The invention in these and other respects can be productively applied to a wide variety of proteins and is particularly useful for making and using self-buffering formulations of pharmaceutical proteins for veterinary and medical use, especially, in particular, for the treatment of diseases in human subjects.
Also published as:
MXMX/a/2007/015476KR1020080031684IL188102SG162788EP1909831ZA2008/00338
JP2008543839US20080311078BRPI0611901JP2013047261CN101217979CA2610839
EA200800050JP2016053061AU2006259664AU2015242973AU2017202889IN5286/CHENP/2007
JP2018048196EP3351269WO/2006/138181